Disc Medicine (IRON) Net Income (2020 - 2026)
Disc Medicine (IRON) posted quarterly Net Income of -$59.5 million for Q2 2026, down 7.76% year-over-year from -$64.5 million in Q2 2025, and up 6.33% quarter-over-quarter from -$63.6 million in Q1 2026.
Analysis
Disc Medicine (IRON) Net Income (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Net Income for 7 consecutive years, with -$59.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Income fell 7.76% year-over-year to -$59.5 million; the TTM figure through Jun 2026 stood at -$201.4 million (down 38.56% YoY), while the FY2025 annual figure was -$167.7 million, down 53.32% from the prior year.
- Net Income advanced to -$59.5 million in Q2 2026 per IRON's latest filing, from -$63.6 million in the prior quarter.
- Across five years, Net Income topped out at -$9.6 million in Q2 2022 and bottomed at -$63.6 million in Q1 2026.
- Historically, Net Income has averaged -$29.1 million across 5 years, with a median of -$24.9 million in 2023.
- On a YoY basis, Net Income climbed as much as 46.27% in 2022 and fell as far as 155.29% in 2022.
- Disc Medicine's Net Income stood at -$11.2 million in 2022, then slumped by 109.41% to -$23.5 million in 2023, then retreated by 25.01% to -$29.4 million in 2024, then surged by 45.59% to -$16.0 million in 2025, then sank by 271.7% to -$59.5 million in 2026.
- Business Quant data shows IRON's Net Income at -$59.5 million in Q2 2026, -$63.6 million in Q1 2026, and -$16.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | -59.53 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -59.53 Mn |
| Mar 31, 2026 | -63.55 Mn |
| Dec 31, 2025 | -16.02 Mn |
| Sep 30, 2025 | -62.32 Mn |
| Jun 30, 2025 | -55.25 Mn |
| Mar 31, 2025 | -34.09 Mn |
| Dec 31, 2024 | -29.44 Mn |
| Sep 30, 2024 | -26.60 Mn |
| Jun 30, 2024 | -26.35 Mn |
| Mar 31, 2024 | -27.04 Mn |
| Dec 31, 2023 | -23.55 Mn |
| Sep 30, 2023 | -14.10 Mn |
| Jun 30, 2023 | -15.92 Mn |
| Mar 31, 2023 | -22.86 Mn |
| Dec 31, 2022 | -11.24 Mn |
| Sep 30, 2022 | -16.15 Mn |
| Jun 30, 2022 | -9.58 Mn |
| Mar 31, 2022 | -9.85 Mn |
| Dec 31, 2021 | 20.25 Mn |
| Sep 30, 2021 | -18.55 Mn |